08:52 AM EDT, 05/14/2024 (MT Newswires) -- Neumora Therapeutics ( NMRA ) said Tuesday it has initiated a phase 2 study to evaluate the efficacy and safety of navacaprant kappa opioid receptor antagonist as a potential treatment for people with bipolar depression.

The company said it expects to report topline data from the mid-stage study in the second half of 2025.

Navacaprant is also in a phase 3 study to potentially treat patients with major depressive disorder, with data anticipated in Q4, according to Neumora.